$226.00
▲ +3.4% Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Charles River Laboratories Earnings Preview: What to Expect
What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?
Charles River Laboratories International (CRL) Expands Cell Therapy Work, Is The Stock Still Undervalued?
Overview
52-week range
$141
$229
97% of range
Avg surprise (last 3)
+14.5%
Avg reaction (last 2)
+9.3%
50% positive
Latest IV / EM
61%
EM ±14.0% · $220 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $2.06 | $1.96 | +5.1% | -12.0% | -0.0% | earnings |
| Sat Sep 27, 2025 | Sep 2025 | $1.10 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $3.12 | $2.50 | +24.8% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $2.34 | $2.06 | +13.6% | — | +18.7% | earnings |
| Sat Sep 28, 2024 | Sep 2024 | $1.33 | — | — | — | — | financials |
| Sat Jun 29, 2024 | Jun 2024 | $1.74 | — | — | — | — | financials |
| Sat Mar 30, 2024 | Mar 2024 | $1.30 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $1.69 | — | — | — | — | financials |
| Sat Jul 1, 2023 | Jul 2023 | $1.89 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | BMO | $2.72 | $3.12 | -12.8% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | $661M | $672M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $120M | — | $134M | $100M | $75M | — | $117M | $152M |
| Net income | $-15M | — | $54M | $52M | $25M | — | $70M | $94M |
| EPS (diluted) | $-0.30 | — | $1.10 | $1.06 | $0.50 | — | $1.33 | $1.74 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $192M | $214M | $207M | $183M | $229M | $195M | $210M | $179M |
| Inventory | $360M | $299M | $303M | $280M | $290M | $279M | $336M | $349M |
| Total current assets | $1.49B | $1.45B | $1.53B | $1.47B | $1.51B | $1.40B | $1.49B | $1.50B |
| Total assets | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B | $4.02B | $4.18B | $4.18B |
| Total equity | $2.94B | $3.16B | $3.41B | $3.35B | $3.19B | $3.46B | $3.78B | $3.72B |